Dermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled "Compositions for the treatment of skin conditions," is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。